Similar articles

• Effects of enhancement and antagonism of 5-hydroxytryptamine activity on metoclopramide-induced aldosterone secretion in man.

  Sommers DK, Meyer EC, van Wyk M. Sommers DK, et al. Res Exp Med (Berl). 1991;191(6):423-7. doi: 10.1007/BF02576697. Res Exp Med (Berl). 1991. PMID: 1775733 Clinical Trial.
• Effect of ketanserin, an inhibitor of 5-HT2 receptors, on the aldosterone-stimulating action of metoclopramide.

  Degli Uberti EC, Trasforini G, Margutti AR, Rotola CA, Bianconi M, Pansini P. Degli Uberti EC, et al. Horm Res. 1983;17(3):160-7. doi: 10.1159/000179692. Horm Res. 1983. PMID: 6343215
• Effects of metoclopramide and tropisetron on aldosterone secretion possibly due to agonism and antagonism at the 5-HT4 receptor.

  Sommers DK, Snyman JR, van Wyk M. Sommers DK, et al. Eur J Clin Pharmacol. 1996;50(5):371-3. doi: 10.1007/s002280050125. Eur J Clin Pharmacol. 1996. PMID: 8839658 Clinical Trial.
• Regulation of plasma aldosterone levels by metoclopramide: a reappraisal of its mechanism from dopaminergic antagonism to serotonergic agonism.

  Rizzi CA, Mierau J, Ladinsky H. Rizzi CA, et al. Neuropharmacology. 1997 Jun;36(6):763-8. doi: 10.1016/s0028-3908(97)00025-7. Neuropharmacology. 1997. PMID: 9225303 Review.
• From metoclopramide to selective gut motility stimulants and 5-HT3 receptor antagonists.

  Sanger GJ, King FD. Sanger GJ, et al. Drug Des Deliv. 1988 Dec;3(4):273-95. Drug Des Deliv. 1988. PMID: 3076395 Review.